Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
October 29, 2024
October 29, 2024
NEW YORK, Oct. 29 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, issued the following news release:
First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and on trajectory for insulin independence
Islet engraftment i . . .
First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and on trajectory for insulin independence
Islet engraftment i . . .